HUD extends foreclosure moratorium for L.A. County wildfire victims
Originally scheduled to expire on April 8 2025, the moratorium prohibits mortgage servicers from initiating or completing foreclosure actions on FHA-insured single-family forward or Home Equity Conversion mortgages in the Los Angeles County Presidential Major Disaster Declaration (PDMDA) area.
The moratorium will now expire on July 7, 2025.
Newsom extends housing access, rebuilding efforts for wildfire victims
HUD also shared these tips for wildfire victims.
Borrowers unable to make their mortgage payments should contact their mortgage servicer for assistance as soon as practical. Borrowers may also contact the FHA Resource Center at (800) CALL-FHA (1-800-877-8339 or TTY 1-800-877-8339) for assistance.
Borrowers and renters who need immediate housing and disaster recovery assistance; HUD-certified housing counselors are prepared to provide guidance on the available options. To find a HUD-approved housing counseling agency, borrowers can use HUD's online search tool or use our phone search by calling (800) 569-4287 or (202) 708-1455 (TTY).
For borrowers whose homes are destroyed or damaged to an extent that requires reconstruction or complete replacement, contact an FHA-approved lender about FHA's Section 203(h) loan program. This program provides 100 percent financing for eligible homeowners to rebuild or purchase new homes.
For borrowers seeking to purchase and/or repair a home that has been damaged, contact an FHA-approved lender about FHA's Section 203(k) loan program. This program allows individuals to finance the purchase or refinance of a house and the costs of repair or renovation through a single mortgage.
HUD Secretary Scott Turner made the announcement while touring a disaster zone in Altadena with Los Angeles Supervisor Kathryn Barger, whose district includes the Altadena area.
'HUD's extension of the foreclosure moratorium is a lifeline for wildfire survivors in Los Angeles County who are facing immense hardship,' Barger said in a statement.
'I appreciate Secretary Turner's leadership and commitment to ensuring that families impacted by these devastating fires have the time and support they need to recover. This critical relief will help stabilize our communities as we work together to rebuild and heal.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
American Press
2 hours ago
- American Press
The Hope Center: Multi-use facility planned for District A
District A in Lake Charles is starting to see the result of investment. A new resilience center is set to be established in the area. The Hope Center will be a multi-use facility that serves as both a year-round community resource and a lifeline during times of disaster. Led by the Greater St. Mary Community Development Foundation, the project represents a major infrastructure investment, economic development and long-term empowerment. The city is providing $2.6 million in disaster recovery funding through a direct allocation from the U.S. Department of Housing and Urban Development (HUD), said Mark Tizano, director of community development, City of Lake Charles. This cooperative endeavor agreement for the allocation was approved by the Lake Charles City Council in July. The facility will be constructed on North First Avenue, between Catherine and Lyon streets, adjacent to where the proposed $8 million Greater St. Mary Missionary Baptist Church will be built. Together, these developments will bring an estimated $11.5 to $12 million to the area, said Rev. Samuel C. Tolbet, Jr., pastor of the Greater St. Mary Missionary Baptist Church and chairman of the foundation's board. He called the Hope Center a 'legacy project' that will improve the lives of those who live and work in the community. The project is under the purview of the foundation and is a non-profit initiative to create a facility that will 'provide hope for people in the community' and connect citizens with resources, especially in times of crisis. 'One of the things I noticed when Hurricane Laura hit, with the utilities off for 30 days, it was hard to find somewhere to get anything to eat in Lake Charles.' When activated during an emergency, the center will offer cooling and charging stations, Wi-Fi access, meal and resource distribution, and a space for nonprofit partners like the Red Cross, Tizano said. Outside of disaster response, it will be a hub for economic development and community programming in a historically underserved area. Plans include a commercial kitchen that will operate as a commissary for food trucks, a second kitchen functioning as a business incubator for small food operators, office space for local nonprofits, and a meeting room that can seat up to 150 people. The project is part of a broader transformation of the district, Tolbert said. The $26 million Enterprise Boulevard Extension Project is designed to encourage pedestrian and vehicular traffic, opening the door for businesses to locate along the corridor, as well as improve drainage, sewer and sidewalk infrastructure. And after decades of planning, the project is finally underway. Tolbert sees it as a catalyst for homeownership, youth development, and neighborhood revitalization. 'In this community, we face ongoing economic disasters,' he said. 'We can't always wait for someone to fly in and fix things. This gives us the opportunity to work together on strategies for long-term change. He served on the council over 20 years ago. The expansion of Enterprise Parkway was discussed before 2025, but was halted by a lack of funding. The passage of the 2023 tax-neutral bond proposition LC Rebound revived the project. He said it is 'amazing' to finally see the project begin to come to fruition. 'I guess you would think, at some point, you would think, I just had a good dream and it's not going to happen. And then all of a sudden, I wake up and it's happening,' he said. 'But it shows what endurance is all about. Remaining committed and building relationships over the years. Whether it's with elected officials, community leaders and other stakeholders. All of that is important in getting these things done.' Currently, the project is estimated to take 18 to 24 months to complete. The community development department will oversee the project to ensure compliance with HUD's reporting standards. Additional projects underway in District A include MGM Development's Calcasieu Heights Senior Living Community, the construction of the Goosport Pool and Project Build-A-Future's Kingman Crossing. Projects currently in design include park improvement for JD Clifton Park, the Enterprise Boulevard Extension Project and the Louisiana Chamber of Commerce Foundation's Business Incubation Center, Tizano said.
Yahoo
4 hours ago
- Yahoo
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in pre-market on Aug. 19, 2025. FDA Gives Green Signal to Wegovy for MASH On Friday, the company announced that Wegovy had been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. The treatment is to be used in combination with a reduced-calorie diet and increased physical activity. First GLP-1 Therapy Approved for MASH The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the ESSENCE Trial The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy's superior efficacy over placebo in improving liver fibrosis. Notably, 62.9% of participants on Wegovy achieved the resolution of steatohepatitis with no worsening of fibrosis compared to 34.3% on placebo. About 36.8% achieved improvement in liver fibrosis without worsening steatohepatitis after 72 weeks versus 22.4% on placebo. The second phase of the trial is expected to conclude in 2029. Market Impact Novo Nordisk confirmed that Wegovy would be immediately available in the United States for MASH treatment. Currently, the only other FDA-approved therapy for MASH is Madrigal Pharmaceuticals' Rezdiffra, which received clearance in 2024. This means Novo Nordisk's Wegovy should make a killing from businesses generated from MASH treatment. NVO-Heavy ETFs in Focus Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) that are heavy on Novo Nordisk. The NVO has solid exposure to ETFs like Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and VanEck Pharmaceutical ETF PPH. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report VanEck Pharmaceutical ETF (PPH): ETF Research Reports Amplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
FDA approves Tonix's Tonmya to treat fibromyalgia
Tonix Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Tonmya (cyclobenzaprine HCl sublingual tablets) to treat fibromyalgia in adults. Fibromyalgia is a chronic pain condition that affects approximately ten million adults in the US, with 80% of those affected being women. Tonmya is a non-opioid analgesic intended for once-daily use at bedtime. It features a sublingual formulation that allows for rapid absorption into the bloodstream. Investigated as TNX-102 SL, Tonmya is a patented formulation of cyclobenzaprine hydrochloride that facilitates rapid absorption and reduces the formation of a long-acting metabolite. The therapy acts as a multifunctional agent, targeting various receptors in the body. The US Patent and Trademark Office has granted multiple patents, ensuring market exclusivity until 2034, with potential extensions until 2044 for related applications. Tonix Pharmaceuticals CEO Seth Lederman stated: 'The FDA approval of Tonmya as a first-line treatment for fibromyalgia represents a landmark advancement for the millions of people in the US suffering from the debilitating pain this condition causes. 'At Tonix, we recognised the transformative potential of pursuing a new approach with Tonmya for fibromyalgia, a chronic overlapping pain condition (COPC), that has gone without innovation for many years.' The approval was based on data from two Phase III clinical trials involving 1,000 participants, which demonstrated that Tonmya significantly reduced daily pain scores compared to a placebo over 14 weeks. Tonmya has been evaluated in three Phase III clinical trials with more than 1,400 patients. The RELIEF and RESILIENT trials were designed as double-blind, placebo-controlled studies to assess safety and efficacy for fibromyalgia treatment. The RELIEF trial enrolled 503 adults, while the RESILIENT trial included 457 participants, both conducted across multiple sites in the US. Tonmya will be accessible to adults in the US with fibromyalgia by the fourth quarter of 2025 In 2023, Tonix Pharmaceuticals and Tonix Medicines acquired two FDA-approved migraine products from Upsher-Smith Laboratories. "FDA approves Tonix's Tonmya to treat fibromyalgia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
